Skip NavigationSkip to Content
Return Return to Search Results

The odyssey of marine pharmaceuticals: a current pipeline perspective

  1. Author:
    Mayer, A. M. S.
    Glaser, K. B.
    Cuevas, C.
    Jacobs, R. S.
    Kem, W.
    Little, R. D.
    McIntosh, J. M.
    Newman, D. J.
    Potts, B. C.
    Shuster, D. E.

  2. Author Address

    [Mayer, Alejandro M. S.; Glaser, Keith B.] Midwestern Univ, Chicago Coll Osteopath Med, Dept Pharmacol, Downers Grove, IL 60515 USA. [Glaser, Keith B.] Abbott Labs, Abbott Pk, IL 60064 USA. [Cuevas, Carmen] R&D PharmaMar, Res & Dev Director, Madrid 28770, Spain. [Little, R. Daniel] Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA. [Kem, William] Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA. [McIntosh, J. Michael] Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA. [Newman, David J.] NCI, Nat Prod Branch, Frederick, MD 21701 USA. [Potts, Barbara C.] Nereus Pharmaceut Inc, San Diego, CA 92121 USA. [Shuster, Dale E.] Eisai Inc, Oncol, Woodcliff Lake, NJ 07677 USA.;Mayer, AMS, Midwestern Univ, Chicago Coll Osteopath Med, Dept Pharmacol, 555 31st St, Downers Grove, IL 60515 USA.;amayer@midwestern.edu
    1. Year: 2010
    2. Date: Jun
  2. Journal: Trends in Pharmacological Sciences
    1. 31
    2. 6
    3. Pages: 255-265
  4. Type of Article: Review
  5. ISSN: 0165-6147
  1. Abstract:

    The global marine pharmaceutical pipeline consists of three Food and Drug Administration (FDA) approved drugs, one EU registered drug, 13 natural products (or derivatives thereof) in different phases of the clinical pipeline and a large number of marine chemicals in the preclinical pipeline. In the United States there are three FDA approved marine-derived drugs, namely cytarabine (Cytosar-U (R), Depocyt (R)), vidarabine (Vira-A (R)) and ziconotide (Prialt (R)). The current clinical pipeline includes 13 marine-derived compounds that are either in Phase I, Phase II or Phase III clinical trials. Several key Phase III studies are ongoing and there are seven marine-derived compounds now in Phase II trials. The preclinical pipeline continues to supply several hundred novel marine compounds every year and those continue to feed the clinical pipeline with potentially valuable compounds. From a global perspective the marine pharmaceutical pipeline remains very active, and now has sufficient momentum to deliver several additional compounds to the marketplace in the near future; this review provides a current view of the pipeline.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.tips.2010.02.005
  3. View record in Web of Science®
  4. WOS: 000279426800003

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at FrederickClose Button

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel